1887
Rapid communications Open Access
Like 0

Abstract

We report on the first documented extensively drug-resistant tuberculosis (XDR-TB) case in Austria, diagnosed this year. The term XDR-TB was used for the first time in March 2006, in a report jointly published by the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) to describe a disease caused by Mycobacterium tuberculosis that was resistant not only to isoniazid and rifampicin (i.e. multi-drug resistant tuberculosis, MDR-TB), but also to at least three of the six classes of second-line anti-TB drugs - aminoglycosides, polypeptides, fluoroquinolones, thioamides, cycloserine, and para-aminosalycilic acid [1,2]. As this definition was dependent on unstandardised drug susceptibility testing (DST) methodologies and did not necessarily distinguish the most difficult-to-treat cases using the current drug armamentarium, it was eventually modified in October 2006 [1]. XDR-TB is now defined as: resistance to at least rifampicin and isoniazid, in addition to any fluoroquinolone, and to at least one of the three following injectable drugs used in anti-TB treatment: capreomycin, kanamycin, and amikacin [3]. .

Loading

Article metrics loading...

/content/10.2807/ese.13.31.18940-en
2008-07-31
2024-03-28
http://instance.metastore.ingenta.com/content/10.2807/ese.13.31.18940-en
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/13/31/art18940-en.htm?itemId=/content/10.2807/ese.13.31.18940-en&mimeType=html&fmt=ahah
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error